近日，第十八届强生免疫消化学术论坛（18th JIS）在山城重庆成功举办，来自炎症性肠病（IBD）领域的近350位临床专家参与了此次学术会议。会上，浙江大学邵逸夫医院曹倩教授以丰富的临床经验和前沿的研究视角，为我们勾勒出一幅IBD药物治疗新视野。报告精华内容整理如下。
参考文献：
1. Caballero Mateos AM, Cañadas de la Fuente GA, Gros B. Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies. J Clin Med. 2025 Feb 25;14(5):1536.
2. 强生宣布特诺雅达®特诺雅®获批成为中国首个治疗活动性克罗恩病的白介素23抑制剂. https://www.xian-janssen.com.cn/news/5155
3. 强生宣布特诺雅达®特诺雅®在华获批成为首个治疗溃疡性结肠炎的白介素23抑制剂.https://www.xian-janssen.com.cn/news/5257
4. Peyrin-Biroulet L, Allegretti JR, Danese S, et al. Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO study. 2025ECCO. OP10
5. Hart A, Panaccione R, Steinwurz F, et al. Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: Results through Week 48 from the phase 3 GRAVITI study. 2025ECCO. OP33
6. Feagan BG, Sands BE, Sandborn WJ, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320.
7. Fourie A, et al. First-in-class oral peptide systemically targeting the IL-23 pathway.J Invest Dermatol. 2023; 143: S190.
8. Danese S, Panaccione R, Abreu MT, et al. Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the true north open-label extension. J Crohns Colitis. 2024;18(2):264–74.
9. Peyrin-Biroulet L, Dubinsky MC, Sands BE, et al. Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: results from the phase 3 ELEVATE UC clinical programme. J Crohns Colitis. 2024;18:1270–82.
10. Noor NM, Bourke A, Subramanian S. Novel therapies in inflammatory bowel disease - An update for clinicians. Aliment Pharmacol Ther. 2024 Nov;60(9):1244-1260.
11. Wetwittayakhlang P, Bessissow T, Lakatos PL. Novel and emerging drugs for the treatment of Crohn's disease: a review of phase II and III trials. Expert Opin Emerg Drugs. 2024 Mar;29(1):19-34.
12. Sandborn WJ, Danese S, Leszczyszyn J, et al. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin Gastroenterol Hepatol. 2023;21(10):2616–2628.e7
13. Vermeire S, Allegretti JR, Kim HJ, et al. Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn's disease: data from the PIZZICATO umbrella study. J Crohns Colitis. 2024;18(Supplement_1):i16.
14. Solitano V, Estevinho MM, Ungaro F, et al. TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review. BioDrugs. 2025 Mar;39(2):171-183.
15. Sands BE, Feagan BG, Peyrin-Biroulet L, et al. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024 Sep 26;391(12):1119-1129.
16. Jairath V, Kierkus J, Duvall GA, et al. Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn’s disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD). 2025ECCO. OP40
17. Tazi J, Begon-Pescia C, Campos N, et al. Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases. Drug Discov Today. 2021 Apr;26(4):1030-1039.
18. Peyrin-Biroulet L, Biedermann L, et al. Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study. 2025ECCO. P0636.
19. Caron B, Netter P, Danese S, Peyrin-Biroulet L. Bispecific antibodies for the treatment in inflammatory bowel disease: an avenue worth exploring? Expert Opin Biol Ther. 2022 Aug;22(8):951-953.
20. Jairath V, Danese S, Haens GD, et al. Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in patients with mild to severe ulcerative colitis. 2025ECCO. OP31.
21. Bertin L, Crepaldi M, Zanconato M, et al. Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management. Therap Adv Gastroenterol. 2024 Dec 19;17:17562848241303651.
22. Guadalajara H, García-Arranz M, Georgiev-Hristov T,et al. Prospect of Cell Therapy for Treating Perianal Fistula, Including Crohn's Disease. Int J Stem Cell Res Ther. 2016; 3: 028.
23. 中国药物临床试验登记与信息公示平台. 登记号 CTR20244264. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml
24. https://clinicaltrials.gov/study/NCT06260163?term=NCT06260163&rank=1
25. https://clinicaltrials.gov/study/NCT05923073?term=NCT05923073&rank=1
EM-183588，Approved date：2025/5/30
本资料为强生创新制药所有，仅供医学药学专业人士参考，未经批准，严禁翻印、转载及传播。
本资料仅用于医学、科学交流，可能涉及尚未在中国获批的产品和适应症。强生创新制药不支持、不鼓励任何未被批准的药品/适应症使用。
本资料中涉及的AE/SS/PQC已按照公司的要求上报。
欢迎投稿！
tougao@medvoices.cn
稿件类型：研究速递，综述译稿，指南/共识，病例分享。
版权属《消化医声》所有。欢迎个人转发分享。其他任何媒体、网站如需转载或引用本网版权所有之内容，须经本网授权同意（加小编微信：GI-2022）。
